undamentalytics Newsletter
Sign in

Rani Therapeutics Holdings, Inc. revenue

Rani Therapeutics Holdings, Inc.'s revenue was $1.6m in fiscal 2025, up 58.9% on the year before. Since fiscal 2020 ($462,000) it has grown at a compound 28.7% a year. Over the last twelve months it was $4.9m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue4622,717001,0281,6334,877
Growth on the year before—+488.1%−100.0%——+58.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Rani Therapeutics Holdings, Inc. $4.9m 306.4% —
Adlai Nortye Group Ltd. $5.0m — —
Bolt Biotherapeutics, Inc. $4.7m 12.8% -11.5%
Inventiva S.a. $5.1m -49.1% —
Entrada Therapeutics, Inc. $4.7m -94.1% —
Ocugen, Inc. $4.6m -3.7% 26.3%

Compare with peers

Head to head: ANL vs RANIBOLT vs RANIIVA vs RANIRANI vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Rani Therapeutics Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rani Therapeutics Holdings, Inc.